Paper
Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma

https://doi.org/10.1016/0959-8049(95)00052-KGet rights and content

Abstract

In vitro and in vivo neuroblastoma models were used to determine whether improvements in tumour targeting in vivo and therapeutic efficacy in vitro could result from the use of no-carrier-added (n.c.a.) [131I]MIBG. Results were compared with use of the conventional therapy MIBG preparation (ex. [131I]MIBG) of lower specific activity which is produced by iodide exchange reaction. The efficacy of n.c.a. [131I]MIBG was compared with that of [131I]MIBG over a range of specific activities by the assessment of neuroblastoma spheroid growth delay. Whereas n.c.a. [131I]MIBG at a radioactivity concentration of 2 MBq/ml prevented the regrowth of 84% of spheroids, toxicity was significantly reduced by the addition of non-radiolabelled MIBG to the incubation medium. The time-dependent biodistribution of n.c.a. [131I]MIBG in nude mice bearing human neuroblastoma xenografts was compared with that of the conventional therapy radiopharmaceutical. The n.c.a. agent gave improved tumour uptake but also significantly greater accumulation in normal tissues known to accumulate MIBG such as heart, adrenal and skin. However, uptake and retention in the blood was unaltered. For all tissues examined, the 3-day cumulative tumour to normal tissue radiation dose ratio was greater for n.c.a. [131I]MIBG. Theoretical calculations were undertaken to predict organ to tumour dose ratios which would result in human neuroblastoma patients with each of the [131I]MIBG preparations. These results suggest that significant therapeutic gain may be achieved by the use of n.c.a. [131I]MIBG as a treatment agent in neuroblastoma.

References (29)

  • S Jacques et al.

    Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one

    Cancer Res

    (1987)
  • LA Smets et al.

    Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells

    Cancer Res

    (1989)
  • RJ Mairs et al.

    The uptake and retention of metaiodobenzylguanidine by the neuroblastoma cell line NB1-G

    Br J Cancer

    (1991)
  • PG Montaldo et al.

    Accumulation, of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms

    Cancer Res

    (1991)
  • Cited by (40)

    • I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma

      2016, Seminars in Nuclear Medicine
      Citation Excerpt :

      The theoretical advantages in using a high specific activity preparation are improved targeting, greater tumor concentration, and decreased potential for pharmacologic effects. The former has been demonstrated in animal models.40,42 At present, limited clinical studies with this reagent have reported it to be safe43 with a lower incidence of nausea, vomiting, and hypertension,44 although a clear advantage of higher tumor targeting has yet to be established.45

    • Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy

      2012, Journal of Controlled Release
      Citation Excerpt :

      Thus, glucosylated PEPE dendrimers can serve as potential delivery system for the treatment of gliomas. To assess in vivo tumor targeting and therapeutic efficacy, neuroblastoma spheroids and nude mice xenografted with human neuroblastoma cells were treated with radioisotope iodine-131-metaiodobenzylguanidine ([130] MIBG) without any added carrier [120]. The drug was uptaken successfully in the tumor in vivo, where it reduced tumor burden, and prevented regrowth of spheroid in vitro, suggesting that the spheroid results correlate well with those in the animal model.

    • Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors

      2011, Seminars in Nuclear Medicine
      Citation Excerpt :

      The absorbed doses in the NET-rich heart and adrenal were also greater by a similar factor. Doses to the liver and lung were higher by 30%-45%, whereas those to the remaining organs were 65%-95% less than those resulting from the administration of ca [131I]MIBG.23 The increased accumulation of activity in tumor achieved by the administration of nca [131I]MIBG corresponded to its greater efficacy.24

    • Radioiodinated metaiodobenzylguanidine (MIBG): Radiochemistry, biology, and pharmacology

      2011, Seminars in Nuclear Medicine
      Citation Excerpt :

      Furthermore, nonradiolabeled molecules can compete with radiolabeled MIBG for NET binding, resulting in reduced tumor cell uptake of [131I]MIBG.58 Therefore, the higher SA and lower concentration of cold carrier in the final drug product enables administration of a more potent (in terms of radioactivity) therapeutic dose that has less potential to saturate the uptake process in tumor cells, thereby maximizing tumoricidal activity for the n.c.a. form of the [131I]MIBG.57 For example, to treat a patient with 800 mCi of [131I]MIBG (SA, 50 mCi/mg) prepared on the basis of isotope exchange method might contain a total MIBG mass of 16 mg (57 μmol).

    View all citing articles on Scopus
    View full text